Peer-reviewedCC BYCureus19 Oct 2026

Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists

Dorota Bartkowiak¹
Barlomiej Jakubczyk²
Adam Lasota³
Lukasz Kopoczynski⁴
Michal Wiesner⁵
Lukasz Wodzinski⁶
Kamil Boguszewski⁷
Hubert Porazinski¹
Agnieszka Młynarska¹
Oskar Ratajski⁸

8 affiliations

¹Medicine, Dr Jan Biziel University Hospital No. 2 in Bydgoszcz, Bydgoszcz, POL
²Medicine, Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Bydgoszcz, POL
³Cardiology, Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II, Zamość, POL
⁴Medicine, Polish Red Cross Maritime Hospital in Gdynia, Gdynia, POL
⁵Medicine, District Health Center Sp. z o.o. in Malbork, Malbork, POL
⁶Medicine, Florian Ceynowa Specialist Hospital, Wejherowo, POL
⁷Medicine, Nowy Szpital w Nakle i Szubinie, Szubin, POL
⁸Internal Medicine, Karol Marcinkowski University Hospital, Zielona Góra, POL

Read full text PDF Cite

Commentary: The “efficacy window” phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis
William V. McCall, Neil A. Burton, Björn Steiniger-Brach
Frontiers in Pharmacology28 Oct 2026Peer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossref
Artificial Intelligence-Guided Extracellular Vesicle Platforms for Diagnosis and Treatment of Chronic Kidney Disease: A Scoping Review and Future Directions
Kumar Digvijay, Henrik Birn, Claudio Ronco
Medicina (Kaunas, Lithuania)28 Sep 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Treatment Strategies and Future Directions for Locally Advanced Pancreatic Cancer
Kevin M. Turner, Jason B. Gurewitz, Jessica M. Frakes +5
Cancers2 Nov 2026Peer-reviewedCC BY 4.0OncologyCrossref
Human dignity and its associations with self efficacy and treatment adherence in adults with type 2 diabetes in Iran
Yasaman Fallah, Narges Hashemi, Mahrokh Keshvari +1
Scientific Reports25 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textEndocrinology & metabolismCrossref
Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
Zhe Fu, Victoria Jackson-Patel, Kathryn Farrand +7
Journal for immunotherapy of cancer21 Oct 2026Peer-reviewedCC BY-NCFull textOncologyEurope PMC

Cite

BibTeX RIS

BibTeX

@article{bartkowiak2026modern,
  title = {{Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists}},
  author = {Dorota Bartkowiak and Barlomiej Jakubczyk and Adam Lasota and Lukasz Kopoczynski and Michal Wiesner and Lukasz Wodzinski and Kamil Boguszewski and Hubert Porazinski and Agnieszka Młynarska and Oskar Ratajski},
  journal = {Cureus},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13668768},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
AU  - Dorota Bartkowiak
AU  - Barlomiej Jakubczyk
AU  - Adam Lasota
AU  - Lukasz Kopoczynski
AU  - Michal Wiesner
AU  - Lukasz Wodzinski
AU  - Kamil Boguszewski
AU  - Hubert Porazinski
AU  - Agnieszka Młynarska
AU  - Oskar Ratajski
PY  - 2026
DA  - 2026/10/19
JO  - Cureus
UR  - https://europepmc.org/article/PMC/PMC13668768
SN  - 2168-8184
ER  -

Related

Cite